Executive Order 13890, signed on October 3, 2019, directed the Department of Health and Human Services to fundamentally reshape Medicare's payment structures and drug pricing mechanisms. The order instructed HHS to modify reimbursement rates for certain healthcare services and to advance negotiations over pharmaceutical prices within the Medicare program. As a directive from the executive branch, the order carried the force of policy implementation without requiring congressional approval, though its specific modifications to payment rates and drug pricing authority operated within existing statutory frameworks governing Medicare administration.
The order's effects fell directly on multiple constituencies with competing interests. Medicare beneficiaries and seniors faced potential shifts in the availability and cost-sharing requirements for certain treatments as payment rates adjusted. Healthcare providers—hospitals, physicians, and clinics—experienced altered revenue streams from Medicare reimbursements, affecting their operational capacity and service provision. Pharmaceutical manufacturers confronted new constraints on pricing negotiation dynamics, though the scope of these negotiations remained limited compared to international precedents or later legislative proposals.
This action emerged within a broader Trump administration pattern of attempting to reshape healthcare delivery and pharmaceutical markets. Viewed alongside subsequent actions like the FDA's authorization of fruit-flavored vapes and the administration's shifts to Title X family planning and vaccine recommendations, the order reflects a recurring approach: executive branch reorientation of regulatory and payment structures, often with limited transparency regarding long-term consequences. The Medicare payment modifications represent an earlier iteration of this strategy, preceding more aggressive healthcare policy interventions that came later in successive administrations.
The action's implementation status remained partial, indicating that while HHS received the directive, full execution faced constraints—whether from bureaucratic resistance, technical complexity, or other obstacles. The order did not face major court challenges during its initial period, though its drug pricing provisions operated within ongoing debates about Medicare's negotiating authority, debates that would intensify in subsequent years as lawmakers pursued more expansive negotiating powers through legislation.
Executive Order 13890: Medicare Payment and Program Changes
🏥 Healthcare · First Term (2017–2021) · 🤖 AI-categorized
President Trump signed Executive Order 13890 on October 3, 2019, directing the Department of Health and Human Services to modify Medicare payment policies and drug pricing negotiations. The order instructed HHS to implement changes to Medicare payment rates for certain services and to advance drug price negotiations. The confirmed direct impact included modifications to Medicare reimbursement structures that affected healthcare provider payments and drug pricing mechanisms within the Medicare program.